Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adlette Inati

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Annals of Hematology|July 11, 2006
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trialZaher K Otrock, Sami T Azar, Wael A Shamseddeen, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|December 9, 2019
Full genome characterization of human G3P[6] and G3P[9] rotavirus strains in LebanonNischay Mishra, Lina Reslan, Mohsen El-Husseini, et al.
British Journal of Haematology|March 28, 2013
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemiaSuthat Fucharoen, Adlette Inati, Noppadol Siritanaratku, et al.
Pediatric Blood & Cancer|September 1, 2016
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantationAdlette Inati, Mario Kahale, Nada Sbeiti, et al.
British Journal of Haematology|November 15, 2013
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermediaAdlette Inati, Mario Kahale, Susan P Perrine, et al.
European Journal of Haematology|January 30, 2026
Efficacy and Safety of Prophylaxis With a Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease-A WIL-31 Study Sub-AnalysisClaudia Djambas Khayat, Leonid Dubey, Adlette Inati, et al.
Hemoglobin|March 9, 2013
Identification of the first mutation in a BRE motif of the β-globin gene and its inheritance with two other α-globin gene mutations in a Lebanese familyAdlette Inati, Hussein A Abbas, Jad Al-Danaf, et al.
The Lancet. Haematology|April 24, 2021
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialBart J Biemond, Anil Tombak, Yurdanur Kilinc, et al.
American Journal of Hematology|March 29, 2014
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseMarvin E Reid, Amal El Beshlawy, Adlette Inati, et al.
World Journal of Gastroenterology|January 14, 2017
Clinical and epidemiological characteristics of norovirus gastroenteritis among hospitalized children in LebanonNada M Melhem, Hassan Zaraket, Khalil Kreidieh, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Annals of Hematology|July 11, 2006
Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trialZaher K Otrock, Sami T Azar, Wael A Shamseddeen, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|December 9, 2019
Full genome characterization of human G3P[6] and G3P[9] rotavirus strains in LebanonNischay Mishra, Lina Reslan, Mohsen El-Husseini, et al.
British Journal of Haematology|March 28, 2013
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemiaSuthat Fucharoen, Adlette Inati, Noppadol Siritanaratku, et al.
Pediatric Blood & Cancer|September 1, 2016
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantationAdlette Inati, Mario Kahale, Nada Sbeiti, et al.
British Journal of Haematology|November 15, 2013
A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermediaAdlette Inati, Mario Kahale, Susan P Perrine, et al.
European Journal of Haematology|January 30, 2026
Efficacy and Safety of Prophylaxis With a Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease-A WIL-31 Study Sub-AnalysisClaudia Djambas Khayat, Leonid Dubey, Adlette Inati, et al.
Hemoglobin|March 9, 2013
Identification of the first mutation in a BRE motif of the β-globin gene and its inheritance with two other α-globin gene mutations in a Lebanese familyAdlette Inati, Hussein A Abbas, Jad Al-Danaf, et al.
The Lancet. Haematology|April 24, 2021
Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialBart J Biemond, Anil Tombak, Yurdanur Kilinc, et al.
American Journal of Hematology|March 29, 2014
A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell diseaseMarvin E Reid, Amal El Beshlawy, Adlette Inati, et al.
World Journal of Gastroenterology|January 14, 2017
Clinical and epidemiological characteristics of norovirus gastroenteritis among hospitalized children in LebanonNada M Melhem, Hassan Zaraket, Khalil Kreidieh, et al.
Pageof 7